CD8A and Sepsis: Several studies have demonstrated that the count of DCs in patients recovering from sepsis gradually normalizes several weeks post-sepsis (63), and treatment with Fms-like tyrosine kinase 3 ligand (FLT3L; also known as Dendritic cell growth factor) has been shown to significantly enhance the number and function of DCs, this, in turn, modulates the responsiveness of CD8 T cells to novel antigens (39).